Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates

• click to rate

  Posted by Two Blokes Mon at 3:30 PM - Filed in Stock - 2 views
  
  Urogen Pharma (URGN) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.97 per share a year ago.